1H,1H,2H,2H-Perfluorodecanol

• Identification
• Experimental evidence
• Physicochemical properties
• ADMET properties
• Chemical-gene interaction
• Descriptors
• Presence in chemical regulation or guideline
• Presence in human biospecimen

Literature identifier	Study type	Test dosage	Effective dosage	Endocrine-mediated endpoints	Systems-level perturbations
PMID:20615422	IVTH	0.0000074 M	-	No significant effects observed	-
	IVTH	0.0000666 M	0.0000666 M	Affects steroidogenesis	Reproductive endocrine-mediated perturbations
	IVTH	0.0000222 M	0.0000222 M	Affects steroidogenesis	Reproductive endocrine-mediated perturbations
PMID:23142464	IVTH	0.0000016 - 0.00005 M	0.0000031 - 0.00005 M	Decreased testosterone levels	Reproductive endocrine-mediated perturbations
	IVTH	0.0000016 - 0.00005 M	0.0000031 - 0.00005 M	Decreased androstenedione levels	Reproductive endocrine-mediated perturbations
	IVTH	0.0000016 - 0.00005 M	0.0000031 - 0.00005 M	Decreased progesterone levels	Reproductive endocrine-mediated perturbations
	IVTH	0.0000016 - 0.00005 M	0.0000031 - 0.00005 M	Decreased 17-OH-progesterone levels	Reproductive endocrine-mediated perturbations
	IVTH	0.0000016 - 0.00005 M	0.0000125 M	Increased estrone levels	Reproductive endocrine-mediated perturbations
	IVTH	0.0000016 - 0.00005 M	0.0000125 M	Increased Dehydroepiandrosterone (DHEA) levels	Metabolic endocrine-mediated perturbations
	IVTH	0.0000016 - 0.00005 M	0.0000125 - 0.00005 M	Increased estradiol levels	Reproductive endocrine-mediated perturbations
PMID:30536526	IVR	10 mg/kg/day	10 mg/kg/day	Decreased liver weights	Hepatic endocrine-mediated perturbations
	IVR	10 mg/kg/day	10 mg/kg/day	Affects the biochemical composition of liver	Hepatic endocrine-mediated perturbations
	IVR	10 mg/kg/day	10 mg/kg/day	Increased thymus gland weights	Immunological endocrine-mediated perturbations
	IVR	10 mg/kg/day	10 mg/kg/day	Affects cytokine signaling	Immunological endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Affects cytokine signaling	Immunological endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Decreased liver weights	Hepatic endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Alterations in immune responses	Immunological endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Affects superoxide dismutase (SOD) levels	Hepatic endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Affects the biochemical composition of liver	Hepatic endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Affects liver function	Hepatic endocrine-mediated perturbations
	IVR	30 mg/kg/day	30 mg/kg/day	Affects cytokine signaling	Immunological endocrine-mediated perturbations
	IVR	30 mg/kg/day	30 mg/kg/day	Decreased liver weights	Hepatic endocrine-mediated perturbations
	IVR	30 mg/kg/day	30 mg/kg/day	Necrosis of liver	Hepatic endocrine-mediated perturbations
	IVR	30 mg/kg/day	30 mg/kg/day	Affects the biochemical composition of liver	Hepatic endocrine-mediated perturbations
	IVR	30 mg/kg/day	30 mg/kg/day	Affects morphology of hepatocytes	Hepatic endocrine-mediated perturbations

---

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.